Nektar Therapeutics
NKTR8.790USD
+8.123+1219.82%
Close 06/09, 16:00（ET）Quotes delayed by 15 min
1.64BMarket Cap
LossP/E TTM
More Details of Nektar Therapeutics Company
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Company Info
Company codeNKTR
Company nameNektar Therapeutics
IPO dateMay 03, 1994
Founded at1998
CEOMr. Howard W. Robin
Number of employees61
Security typeOrdinary Share
Fiscal year-endMay 03
Address455 Mission Bay Boulevard South
CitySAN FRANCISCO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94158
Phone18554826587
Websitehttps://www.nektar.com/
Company codeNKTR
IPO dateMay 03, 1994
Founded at1998
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
63.40K
-2.38%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
18.08K
-3.80%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Corey Davis
Corey Davis
Managing Director
Managing Director
--
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Sandra A. Gardiner
Ms. Sandra A. Gardiner
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Mark A. Wilson, J.D.
Mr. Mark A. Wilson, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
Mr. Roy A. Whitfield
Mr. Roy A. Whitfield
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
63.40K
-2.38%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
18.08K
-3.80%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Corey Davis
Corey Davis
Managing Director
Managing Director
--
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
Rest of world
97.05M
98.60%
United States
1.38M
1.40%
By Business
By Region
No Data
Shareholder
Update time: Sat, May 17
Update time: Sat, May 17
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
BlackRock Institutional Trust Company, N.A.
7.04%
The Vanguard Group, Inc.
6.61%
Nantahala Capital Management, LLC
4.19%
Acadian Asset Management LLC
3.92%
Eventide Asset Management, LLC
3.57%
Other
74.66%
Shareholder Statistics
Shareholder
Proportion
BlackRock Institutional Trust Company, N.A.
7.04%
The Vanguard Group, Inc.
6.61%
Nantahala Capital Management, LLC
4.19%
Acadian Asset Management LLC
3.92%
Eventide Asset Management, LLC
3.57%
Other
74.66%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
24.81%
Investment Advisor
24.76%
Hedge Fund
15.56%
Research Firm
1.46%
Individual Investor
1.29%
Family Office
0.30%
Bank and Trust
0.11%
Pension Fund
0.08%
Venture Capital
0.03%
Other
31.58%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
395
136.30M
73.24%
-65.37M
2024Q4
427
136.20M
73.84%
-69.28M
2024Q3
442
143.71M
78.07%
-57.20M
2024Q2
458
138.43M
75.38%
-54.08M
2024Q1
477
115.32M
62.79%
-91.21M
2023Q4
499
122.94M
64.45%
-94.24M
2023Q3
522
148.15M
77.94%
-68.45M
2023Q2
531
142.56M
75.34%
-88.27M
2023Q1
545
178.73M
94.47%
-35.40M
2022Q4
560
175.49M
93.38%
-32.58M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
13.33M
7.16%
+154.21K
+1.17%
Dec 31, 2024
The Vanguard Group, Inc.
12.33M
6.62%
-792.77K
-6.04%
Dec 31, 2024
Nantahala Capital Management, LLC
7.81M
4.2%
+3.70M
+90.02%
Dec 31, 2024
Acadian Asset Management LLC
7.20M
3.87%
+1.55M
+27.34%
Dec 31, 2024
Eventide Asset Management, LLC
6.65M
3.57%
-2.75M
-29.26%
Dec 31, 2024
PRIMECAP Management Company
5.54M
2.98%
-372.07K
-6.29%
Dec 31, 2024
Renaissance Technologies LLC
3.91M
2.1%
+583.15K
+17.52%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.96M
2.13%
-5.50K
-0.14%
Dec 31, 2024
TCG Crossover Management, LLC
4.00M
2.15%
--
--
Dec 31, 2024
View more
Related ETFs
Update time: Fri, Jun 6
Update time: Fri, Jun 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.52%
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.52%
iShares Micro-Cap ETF
Proportion0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.02%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
